Ignite Creation Date:
2025-12-25 @ 1:26 AM
Ignite Modification Date:
2026-03-02 @ 4:12 AM
Study NCT ID:
NCT01870193
Status:
COMPLETED
Last Update Posted:
2023-02-15
First Post:
2013-05-30
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Glutathione and Fuel Oxidation in Aging
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'D005998', 'term': 'Glycine'}, {'id': 'D003545', 'term': 'Cysteine'}, {'id': 'D000409', 'term': 'Alanine'}], 'ancestors': [{'id': 'D000596', 'term': 'Amino Acids'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D000603', 'term': 'Amino Acids, Sulfur'}, {'id': 'D013457', 'term': 'Sulfur Compounds'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D013438', 'term': 'Sulfhydryl Compounds'}, {'id': 'D021542', 'term': 'Amino Acids, Neutral'}]}}, 'protocolSection': {'designModule': {'phases': ['EARLY_PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'OTHER', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 36}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2013-04-23', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2023-02', 'completionDateStruct': {'date': '2022-08-22', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-02-13', 'studyFirstSubmitDate': '2013-05-30', 'studyFirstSubmitQcDate': '2013-06-03', 'lastUpdatePostDateStruct': {'date': '2023-02-15', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2013-06-05', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2019-03', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Muscle glutathione concentration', 'timeFrame': 'Each subject will be studied over 4 months'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['Glutathione deficiency in aging', 'Impaired mitochondrial fatty-acid oxidation in aging'], 'conditions': ['Aging']}, 'referencesModule': {'references': [{'pmid': '35975308', 'type': 'DERIVED', 'citation': 'Kumar P, Liu C, Suliburk J, Hsu JW, Muthupillai R, Jahoor F, Minard CG, Taffet GE, Sekhar RV. Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial. J Gerontol A Biol Sci Med Sci. 2023 Jan 26;78(1):75-89. doi: 10.1093/gerona/glac135.'}]}, 'descriptionModule': {'briefSummary': 'Glutathione is an important antioxidant protein which protects cells from harmful oxidative stress. Elderly humans are known to have elevated oxidative stress and deficiency of glutathione, but it is not known whether there is deficient synthesis of glutathione in muscle tissue of elderly humans.\n\nMitochondria are engines of cells where food consumed is burned to make energy. Under normal conditions the fuel of choice in the fasted state is fat, but fasted elderly humans are not able to oxidize fat as well as healthy young humans. Elderly humans also have the highest incidence and prevalence of being overweight and obese, and have increased storage of fat in liver and muscle.\n\nThis study will help determine whether\n\n1. elderly humans have diminished synthesis of glutathione in the skeletal muscle, and whether this can be improved by supplementing cysteine and glycine (and not an isonitrogenous placebo) in the diet;\n2. improving muscle glutathione concentrations can also improve fuel oxidation in aging;\n3. improvement of intracellular glutathione concentrations will be associated with a change in total body fat content', 'detailedDescription': "Subjects will be recruited by written informed consent on forms approved by the Institutional Review Board of Baylor College of Medicine at the time of approval of the full protocol. Subjects taking an nonvitamin supplements or lipid lowering medications will stop this 4 weeks before the screening labs and for the entire duration of the study. Fasted subjects will have screening labs (blood count, HbA1c, lipid profile, liver profile, blood urea nitrogen, Creatinine, thyroid stimulating hormone, free t4, cortisol) followed by an oral glucose tolerance test, measures of muscle strength by dynamometry, tests of function (including a 6-min walk test) and body composition scans to measure total body fat. On another occasion, fasted subjects will be undergo stable isotope infusions and other studies in the metabolic research unit to measure concentrations of amino-acids and glutathione in red blood cells and muscle tissue, glutathione synthesis rates in muscle and red cells, plasma and whole-body mitochondrial fatty-acid oxidation, Kreb's cycle function, urine urea nitrogen, plasma reactive oxygen species and F2-isoprostanes, genes of glutathione synthesis and fuel oxidation. Elderly subjects will also have magnetic resonance spectroscopy scan for liver and muscle fat content.\n\nYoung subjects will be given dietary cysteine and glycine for 2-weeks and be restudied 2-weeks later. They are then released from the study.\n\nElderly subjects will be studied for 16 weeks. They will be assigned to receive either cysteine plus glycine, or alanine in a randomized, double-blinded study design. The studies described above will be repeated after 2 weeks and 16 weeks. Subjects will have monthly measures of liver profile, lipid profiles, BUN and creatinine and glutathione."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '80 Years', 'minimumAge': '21 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Elderly subjects: age range 61-80y.\n2. Young healthy subjects: age range 21-40y\n\nExclusion Criteria:\n\n1. Renal impairment (serum creatinine \\>1.5 mg/dL)\n2. Liver impairment (liver transaminases \\>2x upper limit of normal)\n3. Untreated/uncontrolled hyperthyroidism or hypothyroidism\n4. Known hypercortisolemia\n5. Known diabetes mellitus\n6. Hospitalization in the past 3 months\n7. BMI \\<27 (elderly group)\n8. Elderly women on estrogen replacement\n9. Known pre-existing coronary artery disease\n10. Fasted plasma triglyceride \\>300 mg/dl (on lipid lowering medications)\n11. Fasted plasma triglyceride \\>500 mg/dl (off lipid lowering medications)'}, 'identificationModule': {'nctId': 'NCT01870193', 'briefTitle': 'Glutathione and Fuel Oxidation in Aging', 'organization': {'class': 'OTHER', 'fullName': 'Baylor College of Medicine'}, 'officialTitle': 'Glutathione and Fuel Oxidation in Aging', 'orgStudyIdInfo': {'id': 'H-30681 GSH-Aging'}, 'secondaryIdInfos': [{'id': 'R01AG041782', 'link': 'https://reporter.nih.gov/quickSearch/R01AG041782', 'type': 'NIH'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'Young controls', 'description': 'Young controls will be studied before and after receiving cysteine and glycine for 2 weeks', 'interventionNames': ['Dietary Supplement: Glycine, cysteine (as n-acetylcysteine), alanine']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Elderly active', 'description': 'Elderly subjects in the active group will receive glycine plus cysteine (as n-acetylcysteine) for 4 months, and be studied at baseline, 2 weeks and 4 months', 'interventionNames': ['Dietary Supplement: Glycine, cysteine (as n-acetylcysteine), alanine']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Elderly placebo', 'description': 'Elderly subjects in the placebo group will receive alanine for 4 months, and be studied at baseline, 2 weeks and 4 months', 'interventionNames': ['Dietary Supplement: Glycine, cysteine (as n-acetylcysteine), alanine']}], 'interventions': [{'name': 'Glycine, cysteine (as n-acetylcysteine), alanine', 'type': 'DIETARY_SUPPLEMENT', 'description': 'Young controls will receive cysteine plus glycine for 2 weeks\n\nThe elderly subjects will be randomized in a double-blinded design to receive either cysteine plus glycine OR alanine for a period of 4 months', 'armGroupLabels': ['Elderly active', 'Elderly placebo', 'Young controls']}]}, 'contactsLocationsModule': {'locations': [{'zip': '77030', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'Baylor College of Medicine', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}], 'overallOfficials': [{'name': 'R V Sekhar, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Baylor College of Medicine'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Rajagopal V Sekhar', 'class': 'OTHER'}, 'collaborators': [{'name': 'National Institute on Aging (NIA)', 'class': 'NIH'}], 'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorTitle': 'Associate Professor', 'investigatorFullName': 'Rajagopal V Sekhar', 'investigatorAffiliation': 'Baylor College of Medicine'}}}}